207 related articles for article (PubMed ID: 10432284)
21. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
22. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
23. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
24. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
[TBL] [Abstract][Full Text] [Related]
26. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
27. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
28. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
[TBL] [Abstract][Full Text] [Related]
29. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.
O'Neil BH; Kawakami Y; Restifo NP; Bennink JR; Yewdell JW; Rosenberg SA
J Immunol; 1993 Aug; 151(3):1410-8. PubMed ID: 8335937
[TBL] [Abstract][Full Text] [Related]
30. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
Jäger E; Ringhoffer M; Altmannsberger M; Arand M; Karbach J; Jäger D; Oesch F; Knuth A
Int J Cancer; 1997 Apr; 71(2):142-7. PubMed ID: 9139833
[TBL] [Abstract][Full Text] [Related]
31. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele.
Real LM; Jimenez P; Cantón J; Kirkin A; García A; Abril E; Zeuthen J; Ruiz-Cabello F; Garrido F
Int J Cancer; 1998 Jan; 75(2):317-23. PubMed ID: 9462725
[TBL] [Abstract][Full Text] [Related]
32. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.
Seliger B; Ritz U; Abele R; Bock M; Tampé R; Sutter G; Drexler I; Huber C; Ferrone S
Cancer Res; 2001 Dec; 61(24):8647-50. PubMed ID: 11751378
[TBL] [Abstract][Full Text] [Related]
33. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
[TBL] [Abstract][Full Text] [Related]
34. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
35. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of major histocompatibility complex class 1 (MHC-I) from squirrel monkeys (Saimiri sciureus).
Pascalis H; Heraud JM; Fendel R; Lavergne A; Kazanji M
Immunogenetics; 2003 Dec; 55(9):633-9. PubMed ID: 14574519
[TBL] [Abstract][Full Text] [Related]
37. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
38. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
39. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
40. A 3'-transcribed region of the HLA-A2 gene mediates posttranscriptional stimulation by IFN-gamma.
Snyder SR; Waring JF; Zhu SZ; Kaplan S; Schultz J; Ginder GD
J Immunol; 2001 Mar; 166(6):3966-74. PubMed ID: 11238642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
